Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Clinical Pharmacology|December 12, 2018
Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in OncologyMark Farha, Eric Masson, Helen Tomkinson, et al.
Pharmaceutical Statistics|December 10, 2025
Optimizing Dosing Strategies in Cell Therapy With Machine Learning and Exposure-Response IntegrationShuqi Wang, Yunqi Zhao, Jia Li, et al.
Clinical Pharmacokinetics|May 3, 2021
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II StudyJoseph Chen, Melissa T O'Gorman, Lee P James, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 21, 2019
Population pharmacokinetic analysis of danvatirsen supporting flat dosing switchHongmei Xu, Xiao Tong, Ganesh Mugundu, et al.
Oncoimmunology|September 16, 2020
Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysisBoris Shulgin, Yuri Kosinsky, Andrey Omelchenko, et al.
British Journal of Clinical Pharmacology|April 14, 2023
Comprehensive clinical pharmacology characterization of AZD4635 in healthy participants to support dosing considerationsGanesh Moorthy, Gayle Pageau Pouliot, Lorraine Graham, et al.
Frontiers in Immunology|March 19, 2021
Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology ModelVeronika Voronova, Kirill Peskov, Yuri Kosinsky, et al.
Cancer Chemotherapy and Pharmacology|June 20, 2020
Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumorsMats Någård, Mei-Lin Ah-See, Karen So, et al.
Targeted Oncology|June 6, 2023
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid TumorsTodd M Bauer, Kathleen N Moore, Janet S Rader, et al.
The Journal of Allergy and Clinical Immunology|March 7, 2026
An Open-Label Phase 1b/2 Trial of Navenibart, a Long-Acting Plasma Kallikrein Inhibitor for Hereditary AngioedemaAleena Banerji, Timothy Craig, Karl Sitz, et al.
Pageof 2